Journals / Medicine Science / 2016 / Cilt: 5 - Sayı: 2

Targeted Agents in Ovarian Carcinoma

Pages
547–561
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Agents against angiogenesis and receptors of growth factors in addition to signalling cascades and intracellular enzymes could shape the individual treatment protocols for cancer survivors.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Gynecologic malignancies take an important part in female cancers.
📊
Key Findings & Data:Ovarian cancer is the second most common gynecologic cancer with the highest mortality rate in developed countries.
💡
Conclusion & Impact:Agents against angiogenesis and receptors of growth factors in addition to signalling cascades and intracellular enzymes could shape the individual treatment protocols for cancer survivors.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Gynecologic malignancies take an important part in female cancers. Ovarian cancer is the second most common gynecologic cancer with the highest mortality rate in developed countries. Most of the patients need an adjuvant chemotherapy regimen after the initial surgery. Despite their suppressive effect on tumor cells, much toxicity on healthy cells could be seen with these standard chemotherapeutics. In that manner a new way of tumor cell disruption with less toxicity and cancer selective effect is needed, which is called targeted therapy. Moreover this approach could prevent chemo-resistance and increase chemosensitivity of the disease. Primary cytoreductive surgery with platinum based chemotherapy shape the initial management of these tumors. However, recently we are on the edge of molecular therapy for this cancer. In this setting we need to identify a dominant biological pathway for tumor progression and discover a functional and structural molecule within this pathway. The new therapeutic modalities with targeted molecules should build up new perspectives insight tumor cell behaviour. Agents against angiogenesis and receptors of growth factors in addition to signalling cascades and intracellular enzymes could shape the individual treatment protocols for cancer survivors.

🔖

Cite This Article

ÖZ, M., SELÇUK, İ., ARIK, Z., GÜNGÖR, T. (2016). Targeted Agents in Ovarian Carcinoma. Medicine Science, Cilt: 5 - Sayı: 2, 547–561. https://ajindex.com/articles/277507

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (19)

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, CA Cancer Clin. 2013
  2. 63(l):ll-- 30. Oz M, Ozgu E, Korkmaz E, Bayramoglu H, Erkaya S, Gungor T. Utility of frozen section pathology with endometrial pre-- malignant lesions. Asian Pac Cancer Prev. 2014
  3. 15(15):6053--7. Han-Chung Wu D--KC, Chia--Ting Huang. Targeted Therapy for Cancer. Cancer. 2006
  4. 2(2):57--66. Gerber DE. Targeted therapies: new generation of cancer treatments. Am Fam Physician. 2008
  5. 77(3):3 1--9. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. l975
  6. 256(5517):495--7. Maatta JA, Sundvall M, Junttila TT, Peri L, Laine VJ, Isola J, Egeblad M, Elenius K. Proteolytic cleavage and phosphorylation of tumor--associated ErbB4 isoform promote ligand--independent survival and cancer cell growth. Mol Biol Cell. 2006
  7. l7(l):67--79. Knight ZA, Shokat KM. Features of selective kinase inhibitors. Chem biol. 2005
  8. 12(6):621--37. Sapra P, Moase EH, Ma J, Allen TM. Improved therapeutic responses in xenograft model of human lymphoma (Namalwa) for liposomal Vincristine versus liposomal doxorubicin targeted via anti--CDl9 IgG2a or Fab' fragments. Clin Cancer Res. 2004
  9. lO(3):llOO--ll. Bast RC, Jr., Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009
  10. 9(6):415--28. Folkman J. Tumor angiogenesis: therapeutic implications. Engl Med. 1971
  11. 285(21):1182--6. Blume--Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001
  12. 41 l(6835):355--65. Willmott LJ, Fruehauf JP. Targeted therapy in ovarian cancer. Oncol. 2010
  13. 20102740472. Mitri Z, Constantine T, O'Regan R. The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemother Res Pract. 2012
  14. 743193. Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S. Trastuzumab treatment in patients With advanced or recurrent endometrial carcinoma overeXpressing HER2/neu. Int Gynaecol Obstet. 2008
  15. 102(2):128--3l. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nature Med. 2003
  16. 9(6):669--76. Banerjee S, Kaye S. The role of targeted therapy in ovarian cancer. Eur Cancer. 2011
  17. 47(Suppl 3):S116--30. Ramakrishnan S, Subramanian IV, Yokoyama Y, Geller M. Angiogenesis in normal and neoplastic ovaries. Angiogenesis. 2005
  18. 8(2):l69--82. Chen H, Ye D, Xie X, Chen B, Lu W. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol. 2004
  19. 94(3):630--5. Monk BJ, Dalton H, Fa